Medical News, Research & Health Tips
You describe your symptoms. The fatigue that doesn’t go away no matter how much you sleep. The chest tightness that comes and goes. The pain that you know isn’t normal. You’ve tracked it, documented it, and worked up the courage to finally sit in that cold examination room and say, something is wrong.
Wyoming residents who purchased certain generic prescription drugs between 2010 and 2018 may be eligible for compensation from a $39.1 million settlement involving generic drug manufacturers accused of price-fixing and reducing competition.
Arkansas Governor Sarah Huckabee Sanders has signed Senate Bill 189 into law, authorizing the sale of ivermectin for human use without a prescription.
In a letter to acting FDA Commissioner Sara Brenner, Senator Banks highlighted the surge in online markets selling knock-off and counterfeit GLP-1 receptor agonists—medications commonly used for weight loss—that may pose significant health risks to American consumers.
More Articles
- Atorvastatin reduces major cardiovascular events but misses disability-free survival goal
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or dementia, but did not significantly improve disability-free survival, according to results presented in a Hot Line session today at ESC Congress 2026 and published […]
- Digital registry strategy doubles heart failure treatment uptake
A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than doubled implementation of an effective type of heart failure treatment.
- FDA approves daraxonrasib for patients with metastatic pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.
- Functional angiography outperforms conventional imaging in AIR-STEMI trial
Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
- Milvexian fails to reduce cardiovascular events after acute coronary syndrome
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.
- Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.
Entertainment
ADVERTISEMENT
Advertisement Headline
Expand Your Reach!
Advertise with us and connect with a targeted audience. For more information, contact us at [your contact information] or visit [your website].
Complete real estate listings are available here when searching for a new place to stay. It also comes with a complete source of property features for you to choose from as well as pre-approval mortgage rates.
Find the perfect home of your dreams with this #1 site for renters with over a million listings of apartments, houses, condos, and town homes for rent to check out to. Ideal for renters and property owners finding their perfect fit.





